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Abstract
Intraoperative radiotherapy (IORT) refers to the delivery of a single radiation dose to a limited volume of tissue
during a surgical procedure. A literature review was performed to analyze the role of IORT in gynaecological and
genito-urinary cancer including endometrial, cervical, renal, bladder and prostate cancers.
Literature search was performed by Pubmed and Scopus, using the words “intraoperative radiotherapy/IORT”,
“gynaecological cancer”, “uterine/endometrial cancer”, “cervical/cervix cancer”, “renal/kidney cancer”, “bladder
cancer” and “prostate cancer”. Forty-seven articles were selected from the search databases, analyzed and briefly
described.
Literature data show that IORT has been used to optimize local control rate in genito-urinary tumours mainly in
retrospective studies. The results suggest that IORT could be advantageous in the setting of locally advanced and
recurrent disease although further prospective trials are needed to confirm this findings.
Keywords: Intraoperative radiotherapy, Endometrial cancer, Cervical cancer, Renal cancer, Bladder cancer, Prostate cancer
Background
Intraoperative radiotherapy (IORT) refers to the delivery
of a single large dose of radiation to a limited volume of
tissue during a surgical procedure.
Radiotherapy (RT) has a major role in the management
of most gynaecological and genito-urinary cancer as adju-
vant or neoadjuvant treatment or as radical treatment in
combination with chemotherapy or hormone therapy.
IORT has the capability to increase the radiation dose with
very limited or no increase of toxicity thanks to the target
exposition during the surgical procedure. For this reason,
IORT can be used in various settings of gynaecological
and genito-urinary tumours aiming at dose intensification
and consequently at increasing tumour control rate.
IORT can be delivered using dedicated linear accelerator
producing electron beams, X-rays sources delivering low-
energy radiation or high dose-rate brachytherapy units
through catheters positioned in the tumour bed and loaded
with iridium-192. In particular, electrons generated by linacs
and brachytherapy sources can be conveniently used for IORT
procedures in gynaecological and genito-urinary tumours.
Interestingly, the first IORT experience was indeed
reported in 1905 for the treatment of a 33 year old woman
affected by uterine carcinoma [1]. Over the following
decades, IORT was increasingly used for several tumours
including gynaecological and genitor-urinary malignancies.
In 1998, the International Society of Intraoperative
Radiation Therapy (ISIORT) was founded in order to pro-
mote a scientific and professional approach to IORTactivity.
Among their other activities, ISIORT-Europe collected and
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recorded information regarding IORT treatments, includ-
ing those of gynaecological and genito-urinary cancers,
from the affiliated centres in a database registry [2, 3].
This review focuses on the use of IORT in genito-urinary
malignancies, reporting tumour setting and outcome for
endometrial, cervical, renal, bladder and prostate cancers.
Research criteria
Literature search was performed through Pubmed and
Scopus databases by using the following key words: “intraop-
erative radiotherapy/IORT”, “gynaecological cancer”, “uter-
ine/endometrial cancer”, “cervical/cervix cancer”, “renal/
kidney cancer”, “bladder cancer” and “prostate cancer”.
Eighty-four articles were found from 1981 to 2015. Reviews
and case reports were excluded as well as clinical series pre-
sented as abstract at conferences proceedings. Forty-seven
articles were finally selected for the review.
Endometrial and cervical cancers
Patients with endometrial and cervical cancer are usually
treated with surgery and RT with or without chemother-
apy depending on risk factors. After primary treatment,
the risk of local failure is up to 60% [4] and the options
for a new treatment are surgery, RT when a reirradiation
is feasible, and chemotherapy. After such treatments,
disease control has been reported in 25–50% and
18–47% in patients with recurrent endometrial and cer-
vical cancer, respectively [5]. In these recurrent patients,
IORT after surgical resection can been considered to
increase the probability of local control, especially when
a repeated course of EBRT is not feasible. This treatment
approach including IORT is reported in the NCCN
guidelines with an evidence of category 3 [6].
The use of IORT in the management of endometrial
and cervical cancer was explored in 15 studies, most of
them analysing retrospectively patients affected by lo-
cally advanced primary and recurrent disease. The ma-
jority of articles reported on the clinical experience from
the Mayo Clinic and the University Hospital Gregorio
Marañón in Madrid [7–21] (Table 1). In these clinical
series, IORT was delivered to the tumour bed with elec-
trons in the majority of cases and with low kV x-rays or
brachytherapy through catheters implanted during the
surgical procedure and uploaded with iridium wires in
postoperative setting in selected patient series.
In endometrial cancer patients, limited loco-regional re-
currences have a relatively high control rate of about 60%
at 5 years either with pelvic exenteration or local EBRT in
non-previously irradiated patients [22, 23]. In this tumour
setting, the use of IORT was reported in retrospective
studies [14, 15]. Dowdy et al. [14] found that radical resec-
tion of the pelvic sidewall with negative margins and
IORT resulted in a relatively high overall survival rate
(71%) (Table 1). Awtrey et al. [15] reported that the
addition of IORT to cytoreductive surgery in 27 recurrent
endometrial cancer patients resulted in a 2-year disease
free survival (DFS) rate of 78% versus 67% when IORT
was not used, although this difference was not statistically
significant. Based on these retrospective data, the addition
of IORT to surgery could be proposed in patients with iso-
lated endometrial cancer recurrences, especially when
margins might be close or microscopically positive.
Patients with a loco-regional recurrence of cervical cancer
and candidates for salvage surgery can undergo also IORT
with the intent to sterilize the possible residual disease and
improve the outcome. This approach was described in three
series from Mahe et al. [20], Barney et al. [10] and
Martinez-Monge et al. [16] who reported globally the results
in 188 patients with recurrent cervical cancer. Intraoperative
radiation dose ranged from 6 Gy to 30 Gy, with higher doses
in case of macroscopically positive margins (R2). Mahe et al.
[20] reported a slightly higher local control, although statisti-
cally not-significant, in patients with radical resection versus
those who received partial resection (27% vs. 11%), Barney
et al. [10] did not observe any influence of margins status
for local control and Martinez-Monge et al. [16] reported a
risk of distant metastases of 38% in patients with negative
margins (R0) and 100% in those with macroscopic residual
disease (R2). From these studies, it emerged that the status
of the margins is the most important risk factor for treat-
ment and the association of IORT seems to improve the
probability of local control.
As far as locally advanced primary cervical cancer is
concerned, two series treated by IORT are reported in the
recent literature [12, 16]. In both studies, patients under-
went radical hysterectomy and 10–25 Gy IORT after neo-
adjuvant EBRT, concomitantly to chemotherapy, to a total
dose of 50.4 Gy. In the Giorda's phase II trial, patients tol-
erated radio-chemotherapy quite well, but developed high
incidence of toxicity (79%) after surgery and IORT [12]. In
the Martinez-Monge's retrospective series, 15% of side ef-
fects were related to IORT [16]. The available data sug-
gests that this aggressive strategy is not advantageous in
particular for the risk of severe side effects and that con-
comitant radio-chemotherapy alone should be considered
the best treatment strategy in this patient setting [6].
In conclusion, literature data supports the use of IORT
in recurrent endometrial and cervical cancer to improve
local control whereas its use appears more controversial
in primary locally advanced disease. The potential bene-
fit of this approach is mainly based on retrospective
mono-institutional studies and should be further verified
by prospective possibly randomized trials investigating
the potential advantage compared to EBRT alone.
Renal cancer
Historically, the standard therapy for renal cell carcin-
oma is radical nephrectomy. Local control and survival
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rates after surgery alone are satisfactory for T1-T2 N0
with rates of 90-100% and 80-90% at 5 years, respect-
ively. The results are less favourable for locally advanced
and N+ disease, where the 5-year local control rate and
overall survival rates are 70-80% and 0-40%, respectively.
In renal cancer, the isolated local recurrence after radical
nephrectomy is uncommon (0.7-3.6%) but it is associ-
ated with a poor prognosis. An aggressive surgical
approach to local advanced or recurrent disease, possibly
including the removal of the renal fascia and leading to
negative margins, seems to improve outcome and pro-
long survival [24, 25].
Although renal cell carcinoma has traditionally
been considered relatively radiation resistant, recent
data using hypofractionation for primary or meta-
static lesions suggest that this resistance can be over-
come by high dose per fraction, as used in the IORT
scenario [26].
The role of IORT in the management of renal cancer
was explored in a number of retrospective studies with
patients presenting with locally advanced primary or
recurrent disease [27–33] (Table 2). IORT doses varied
from 10 to 25 Gy depending on the amount of residual
tumour after maximal resection and on the dose of the
combined EBRT. All cases of these series were charac-
terized by postoperative microscopic or macroscopic
residual disease in the renal fossa. A more recent study
[27] considered 98 patients with advanced or recurrent
renal cell carcinoma treated with IORT at nine institu-
tions. Preoperative or postoperative EBRT to a total
dose of 40–50.5 Gy was administered to 27% or 35% of
patients, respectively. The median radiation dose
administered with IORT was 15 Gy (range: 9.5-20 Gy).
Overall survival and disease free survival rates at 5 years
were quite similar and only 24% of relapses were local
whereas 76% were distant. This fact suggests the poten-
tial benefit in local control when IORT is added. Similar
results in terms of local control rates were reported in pre-
vious studies from other institutions (Table 2). In these
series, the acute and late toxicity profile seems acceptable.
Many studies, however, are characterized by a limited de-
scription of late side effects.
From all published data, although from retrospect-
ive series, it emerges that the addition of IORT to
surgery and EBRT is associated with high rates of
local control with acceptable toxicity. The best candi-
dates could be untreated patients with large tumour
volume and high risk of positive margins after radical
nephrectomy and patients with locally recurrent
tumours. The long-term prognosis is mainly related
to the risk of onset of distant relapse that is quite
common, especially in patients with recurrent disease.
This fact advocates the need for additional systemic
effective therapy.
Bladder cancer
The goals of treatment for invasive bladder cancer are
high long-term overall and disease-free survival rates
with acceptable functional outcome, however, radical
cystectomy, that is nowadays the standard, needs urinary
diversion and results in erectile impotence and infertil-
ity. In order to avoid these adverse effects and preserve
quality of life, bladder-preserving treatments have been
proposed as a viable option in selected patients [34].
Bladder preservation strategies for muscle invasive blad-
der cancer evolved over time from single modality to
multimodality treatment approaches, including trans-
urethral resection and chemo-radiation protocols. The
use of an intraoperative radiation boost by brachyther-
apy or electrons may be advantageous for intensifying
the dose and obtaining local control without comprom-
ising organ function.
From the literature databases, 15 studies using IORT
by brachytherapy implants or electrons were selected for
this review [35–49] (Table 3). Brachytherapy was the
most used intra-operative modality and was employed
either as a single treatment or as a boost dose combined
with EBRT. It may represent a curative treatment for
selected high-risk superficial and solitary muscle infil-
trating tumours. Clinical target volume (CTV) typically
includes the macroscopic disease or the tumour bed
with safety margin to full thickness of the bladder wall.
All the studies about brachytherapy were retrospective
analyses of single or multiple co-operative centres. In
2012, a multicentre survey [36], assessed the role of
brachytherapy in 1040 patients with early stage bladder
carcinoma in a muldisciplinary setting. Patients were
treated by pre-operative EBRT and limited surgery with
brachytherapy implant. From this analysis, it emerged
that this approach can offer adequate results in terms of
local control and overall survival in selected patients
suitable (Table 3). In this regard, a careful patient selec-
tion is particularly important in relation to the non-
negligible probability of acute toxicity leading to fistulas
or necrosis.
A recent systematic review with meta-regression analysis
showed better results after brachytherapy than after cystec-
tomy in terms of overall survival, but not in terms of cause-
specific survival in patients with muscle-invasive bladder
cancer. The authors commented that this discrepancy can
be explained at least in part by the differences in tumour
stage between the two groups [50].
The integration of an IORT boost to the whole bladder
in a multidisciplinary protocol combining neoadjuvant
systemic chemotherapy, preoperative RT, and planned
cystectomy has proven to be feasible in the Pamplona's
series [44]. The mean sterilization rate of invasive blad-
der cancer, confirmed in pathologic studies by the cyst-
ectomy specimen, was 65%, and seemed to be increased
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by the addition of neoadjuvant chemotherapy. This find-
ing can be of importance with respect to the develop-
ment of new protocols aiming at bladder preservation.
In the Lyon series [42], an excellent bladder preservation
rate of 69% was achieved with the combination of pre-
operative chemo-RT followed by IORT. This is the only
prospective study about IORT in bladder carcinoma. It
could be of interest to attempt verifying these results in
further studies using an IORT approach.
In conclusion, after a careful patients selection, IORTcould
be used within a bladder sparing multidisciplinary approach
because of the favourable 5-year local control rates aiming at
escalating the radiation dose. IORT might have a role also in
case of radical surgery for locally advanced disease in order
to improve local control rates, as performed in the Pamplo-
na’s series. Multicentric prospective studies could useful to
confirm the role of IORT in this tumour setting.
Prostate cancer
The rationale for dose escalation with IORT in prostate
cancer is based on the demonstration of a dose–response
relationship and a low α/β value in the radiobiological lin-
ear quadratic model [51]. Likewise, the exploitation of this
principle is being increasingly investigated in EBRT with
hypofractionation [52].
Among 14 IORT literature studies, 9 clinical series
and the ISIORT registry were selected and presented in
Table 4 [2, 53–61].
Early data on IORT in prostate cancer came from the
Kyoto University and the Saitama Cancer Centre in Japan,
where the authors treated patients through a perineal IORT
approach without prostatectomy [59, 61]. More recent ex-
periences were reported by Italian authors using IORT in
combination with radical prostatectomy and regional
lymph node dissection before or after the surgical proced-
ure [53–56]. A relevant percentage (81%) of patients was
included in prospective institutional study protocols as de-
scribed in the ISIORT data-registry [2]. From this analysis,
it emerged that IORT was used as a boost dose prior to
prostate removal in most cases. When a single-shot radi-
ation strategy was adopted, a dose of 18–21 Gy was deliv-
ered, similarly to the breast cancer model. The diameter
and bevel end angle of the applicators were selected based
on target dimensions, considering a margin of at least 5 mm
around the prostate and the necessity to reach the target
underneath the pubic arch while sparing the bladder. The
electron beam energy, between 9 and 12 MeV, depended on
Table 3 IORT studiesfor bladder cancer
Reference N. pts Stage EBRT Treatment Local control (5 years) Overall survival 5-years Toxicity
Hallemeier [35] 11 Local recurrence Neoadjuvant Surgery + IORT
(12.5 Gy)
51% 16% NA
Koning [36] 1040 T1-T2 Neoadjuvant surgery, Ir-192
(25–40 Gy)
75% 62% Fistula 24, ulcers/
necroses 144
van Onna [37] 111 T1-T2 Neoadjuvant Ir-192 (40 Gy) NA 70% Fistula 5
GU 5
van der Steen-Banasik
[38]
76 T1-T2 Neoadjuvant Cs-137, Ir-192
(30–60 Gy)
70% 57% NA
Blank [39] 122 T1-T2-T3 Neoadjuvant Ir-192 (20–
70 Gy)
76% 73% GU 5
Nieuwenhuijzen [40] 108 T1-T2 Neoadjuvant Ir-192 73% 62% NA
De Crevoisier [41] 58 T1-T2-T3 Neoadjuvant surgery, Ir-192
(60 Gy)
65% 60% 5 major late
toxicities
Gerard [42] 27 T2, T3 No Surgery + IORT 85% 53% NA
Pernot [43] 82 T1, T2, T3, T4, Tx Neoadjuvant surgery Ir-192
(30–50 Gy
78% 73% 7 late toxcities≥ G3
Calvo [44] 40 T2, T3, T4 Neoadjuvant surgery + IORT
(15 Gy)
NA 68% NA
Rozan [45] 205 T1-T2-T3 Neoadjuvant surgery Ir-192
(30–50 Gy
NA 77.4% T1, 62.9% T2,
46.8% T3
haematuria, fistula,
chronic cystitis 29
Batterman [46] 85 T2 Neoadjuvant Ra-226 74% 55% NA
Mazeron [47] 24 T2 Adjuvant surgery, Ir-192 92% 58% NA
van der Werf-Messing
[48]
328 T2 Neoadjuvant Ra-226 77% 56% NA
Matsumoto [49] 28 T2 Adjuvant IORT 82% 62% NA
Pts patients, EBRT External beam radiation therapy, Ra-226 brachytherapy, radium needles, Ir-192 brachytherapy, afterloading iridium, IORT intraoperative electron
radiation therapy
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the depth of the target and the position of the rectum, which
should be spared.
Patient selection varied widely in the various studies.
The Japanese series included either early or advanced
stage disease and in particular the Kyoto University in-
cluded stages from A2 to C treated with curative intent
and even stage D2 treated with palliative intent [59, 61].
The Italian studies accrued only non-metastatic locally
advanced disease based on the identification of pre-
operative risk factors.
In terms of post-surgical early and late side effects,
IORT for prostate cancer resulted an acceptable pro-
cedure. In the Japanese series, toxicity resulted in early
haematuria, pollakiuria but only very few cases of late
chronic cystitis and urethral stricture. Interestingly,
Kato et al. reported a reduction in rectal toxicity by
using a spacer to reduce the dose to the anterior rectal
wall [57].
In the Italian series, surgical complications, such as
haematoma and lymphocele, occurred with a similar
incidence to that of conventional prostatectomy [53–56].
No major surgical complications were described and
patients had no significant difference of estimated blood
loss and need of transfusion. In this regard, Rocco et al.
reported post-surgical complications in 42% of patients
after surgery and IORT and in 30% after prostatectomy
alone [54].
Although the relatively short follow-up, the outcome in
terms of biochemical disease free survival was quite prom-
ising resulting higher than 70% in both the Japanese and
Italian series (Table 4). Of note, a recent update of our
clinical series of 95 patients showed a 5-years biochemical
disease-free survival rate of 78% in high-risk patients (oral
presentation at ISIORT-ESTRO Forum, Barcelona, 24–28
April, 2015).
Clinical trials with long follow-up are needed to assess
the real efficacy of IORT in locally advanced prostate can-
cer but preliminary results look quite promising. The best
candidates for IORT possibly combined with EBRT, could
be the patients staged T3N0 with high risk for positive
margins. In the future, multicentre studies should be
designed to better clarify the real role of IORT for dose
escalation in local advanced prostate cancer patients.
Conclusions
The delivery of a high single dose of radiation to a limited
volume during the surgical time, achievable with IORT, is
Table 4 IORT studies for prostate cancer
Reference N. pts Patients’ selection Surgical approach IORT dose (Gy) Technique Adjuvant EBRT BRFS Overall survival Toxicity
Krengli (ISIORT)
[2]
108 Intermediate-high
riska
NA 8-15 Gy with
EBRT 18–21
Gy single shoot
IORT or
50-KV
NA NA NA NA
Krengli [53] 38 Intermediate-high
riska
Retropubic approach
IORT + Prostatectomy
10-12 Gy IORT 46-50 Gy,
2 Gy/fx
82% 2-years 100% Lymphocele 16%
hematoma 6%
Rocco [54] 33 Intermediate-high
riska
Retropubic approach
IORT + Prostatectomy
12 Gy IORT 45 Gy, 1.8
Gy/fx
97% 2-years 100% GU: 17%≥ G2
GI: 10%≥ G2
Saracino [55] 34 Intermediate riska Retropubic approach
Prostatectomy + IORT
16-22 Gy IORT No 77% NA No GU/GI
toxicities≥ G1
Orecchia [56] 11 High-riska Retropubic approach
IORT + Prostatectomy
12 Gy IORT 45 Gy, 1.8
Gy/fx
NA NA No GU/GI
toxicities≥ G1
Kato [57] 54 Stage B2-D1b Perineal/retropubic
No prostatectomy
25-30 Gy IORT 30 Gy, 2
Gy/fx
74% NA Early GI G3: 7%
Higashi [58] 35 Stage B-C b Perineal/retropubic
No prostatectomy
25-30 Gy IORT 30 Gy, 2
Gy/fx
NA 5-years 87%
(stage C)
5-years 92%
(stage B)
NA
Abe [59] 21 Stage B2-days b Perineal 28-35 Gy or
20–25 Gy
(if combined
with EBRT)
IORT 50 Gy NA 5-years 72% GU: 100% early
ematuria 10%
early pollakiuria
Kojima [60] 30 Stage B-C b Perineal/retropubic
No prostatectomy
– IORT NA NA 5-years 43% NA
Takahashi [61] 14 Stage B2-days b Perineal
No prostatectomy
28-35 Gy or
20–25 Gy
(if combined
with EBRT)
IORT 50 Gy NA NA 0%
pts patients, GU genito-urinary, GI gastro-intestinal, BRFS biochemical relapse-free survival, NA not available
aNational Comprehensive Cancer Network (NCCN) guidelines NCCN [6]
bWhitemore-Jewett staging system [Whitmore 1956, Jewett 1975]
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useful to avoid normal tissues not at risk of microscopic dis-
ease. For gynaecological and genito-urinary cancers, IORT is
not a standard treatment but it may be considered a treat-
ment option in selected patients.
In endometrial, cervical and renal cancers, IORT can
be used mainly in recurrent disease, whereas in bladder
carcinoma it may be part of an organ-sparing treatment
approach aiming at patient quality of life preservation.
In the case of prostate cancer, IORT can be used in
locally advanced high risk disease possibly combined
with EBRT to intensify the radiation dose in the attempt
to improve long term local control and possibly increase
biochemical disease-free and overall survival.
The available literature data are interesting but the
present review shows that the majority of published clin-
ical studies are mono-institutional, retrospective and
often included a limited number of patients. In order to
overcome these limitations, large multicentre collabora-
tions should be established to design prospective clinical
trials aiming at better defining the role of IORT in
tailored multimodality therapeutic approaches for gynae-
cological and genito-urinary tumours. For this purpose,
the ISIORT could serve as a basis for future collabor-
ation and the ISIORT-Registry could be a platform for
sharing data and promote clinical research.
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